The red striped softscale insect (RSSI) infestation in the Philippines spread to 2,249.48 hectares of sugarcane farms as of June 5. That was an increase of 460.55 hectares, or 25.74%, from a week earlier. The number of affected farmers rose by 239, while 23 more barangay (villages) were reported infested, according to the Sugar Regulatory Administration.

Gazexport, a significant shareholder of Tethys Petroleum Limited, said a Kazakhstan court revoked a Tethys subsidiary’s Akkulkovskoye oil field license in September 2025 after finding regulatory shortcomings, including incomplete geological work and late or deficient reporting, and an appeal was later dismissed. The field was estimated to have about 14.1 million barrels of remaining C1 recoverable reserves as of 2010, which under current market assumptions could translate into more than $417 million in potential revenue. Gazexport described the development as a single-asset setback that does not materially reduce global crude supply but could prompt a reassessment of compliance risk in Central Asian resource jurisdictions.

Circle Logistics said the U.S. auto industry is facing a severe aluminum shortage that has forced multiple automakers to halt production. Semiconductor shortages and extended lead times for critical parts have also stretched to 8–12 weeks, adding to structural strain across supply chains. The company said it is providing expedited emergency parts transportation for automotive and construction customers through its 32 locations and specialized freight capacity. The report cited aluminum scarcity as a key manufacturing bottleneck and did not discuss price or supply-demand shifts in other tradable traditional assets.

Action Energy Company (Bloomberg: ALFTAQA KK) said on May 16 it secured a combined KWD 40.9 million (about $135 million) in credit facilities from two Kuwaiti banks. The funding will support the deployment of seven new drilling rigs—two 750 HP, four 1,500 HP and one 1,000 HP—tied to contracted projects with Kuwait Oil Company (KOC). The company reported first-quarter net profit of KWD 2.2 million, up 150% year on year, and said its rig count rose to 20 in Q1 2026 from 13 in Q1 2025.

ASML carried out share repurchases over five trading days from June 8 to 12, buying back about 51,566 shares in total. The weighted average purchase prices ranged from €1,481.52 to €1,601.76 per share. Daily repurchased values were around €15.87 million. The transactions were made under the company’s share buyback program announced on 28 January 2026.

Core AI Holdings (Nasdaq: CHAI) said it has appointed John Clinton Haley, CEO of Allianca Group and a former Meta Platforms leader, to its advisory board. The company said Haley has overseen the delivery of more than 720 MW of mission-critical data center capacity globally and supported annual project portfolios exceeding $6 billion. Core AI said the appointment follows its recently announced strategic joint venture with Allianca aimed at accelerating development of AI-ready data centers to meet demand for next-generation compute capacity.

Surge Copper released a pre-feasibility study (PFS) for its Berg copper project, outlining 1.2 billion tonnes of reserves containing 5.8 billion pounds of copper, 687 million pounds of molybdenum and 160 million ounces of silver. In the base case, the study estimates an after-tax NPV8% of C$4.6 billion and a 24% IRR. Using spot prices as of June 2026, the NPV8% rises to C$9.4 billion and the IRR to 36%. The company said Berg is among Canada’s largest undeveloped copper projects and can be developed as a standalone operation with low cash costs.

Elicio Therapeutics said its Phase 2 AMPLIFY-7P study of ELI002 7P in adjuvant pancreatic cancer missed the prespecified primary endpoint of disease-free survival in the intent-to-treat population, citing an imbalance in R1 resection patients (19% vs 10%). In a post-hoc analysis, the R0 completely resected subgroup, which made up about 84% of the study, showed a disease-free survival benefit (HR 0.65, p=0.048) and mKRAS-specific T-cell responses were strongly associated with clinical outcomes. The company said it has refined its Phase 3 strategy to focus on R0 patients and extend dosing, without disclosing new financing or regulatory milestones.